Eileen Knox, APRN
Family · Waterbury, CTNPI 1831523638
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.7% of the total across 450 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 35 manufacturers, the largest accounting for just 16.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $2,725 and has fallen 97.1% since, to $80 in 2025. Among family clinicians in CT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 450 payments — averaging $18.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$1K
- Astellas Pharma US Inc$586
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$578
- Bayer$569
- Novo Nordisk$568
- Boehringer Ingelheim$510
- plus $4K from 29 others
What the payments were for
- Food & beverage$8,16599%
- Education$1041%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 73 | $1,397 |
| Astellas Pharma US Inc | 29 | $586 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 40 | $578 |
| Bayer | 28 | $569 |
| Novo Nordisk | 33 | $568 |
| Boehringer Ingelheim | 28 | $510 |
| AstraZeneca(2 entities) | 27 | $478 |
| Lilly USA, LLC | 24 | $471 |
| Amarin Pharma, Inc. | 23 | $412 |
| AbbVie | 15 | $354 |
| Merck | 19 | $325 |
| Johnson & Johnson | 21 | $298 |
| Amgen | 15 | $291 |
| Pfizer | 12 | $251 |
| Kowa Pharmaceuticals America, Inc. | 10 | $164 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $151 |
| Novartis | 5 | $121 |
| Idorsia Pharmaceuticals US Inc | 6 | $115 |
| E.r. Squibb & Sons, L.L.C. | 6 | $111 |
| Sanofi-aventis U.S. LLC | 5 | $92 |
| Genentech USA, Inc. | 4 | $67 |
| Exact Sciences | 3 | $67 |
| Redhill Biopharma Inc. | 3 | $46 |
| Eisai Inc. | 2 | $34 |
| Sumitomo Pharma America, Inc. | 1 | $23 |
| Sanofi Pasteur Inc. | 1 | $23 |
| Intercept Pharmaceuticals, Inc. | 1 | $22 |
| Abbott | 1 | $22 |
| Phathom Pharmaceuticals, Inc. | 1 | $22 |
| Ascensia Diabetes Care US Inc. | 1 | $21 |
| Otsuka America Pharmaceutical, Inc. | 1 | $19 |
| IBSA Pharma Inc. | 1 | $19 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $17 |
| Eyevance Pharmaceuticals LLC | 1 | $12 |
| Hikma Pharmaceuticals USA | 1 | $12 |
How this compares
$8,270 in reported general payments places this provider in the 95th percentile of 1,596 family providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 11 | $29,642 |
| VascepaIcosapent Ethyl | 20 | $7,854 |
| Zolpidem Tartrate | 85 | $533 |
| Pantoprazole Sodium | 40 | $492 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 20 | $441 |
| Atorvastatin Calcium | 30 | $431 |
| Levothyroxine Sodium | 31 | $425 |
| Pregabalin | 17 | $424 |
| Metoprolol Succinate | 32 | $361 |
| Tramadol Hcl | 53 | $286 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 16 | $279 |
| Rosuvastatin Calcium | 45 | $275 |
| Eszopiclone | 18 | $234 |
| Losartan Potassium | 20 | $228 |
| Lorazepam | 65 | $216 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $568 | $29,64211 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,596 family providers in Connecticut.
Other family in Waterbury
- Elisha ChristiansonWaterbury$371K
- Lauren PeruginiWaterbury$13K
- Kathleen SullivanWaterbury$12K
- Kathryn TierneyNew Britain$140K
- Jennifer SilvaSouth Windsor$91K
- Carli WillardEnfield$74K
- Erin MartinMilford$70K
- Dayna GiordanoNew Haven$65K
- Diana BytyqiDerby$53K
- Farhiya AbdiSouth Windsor$30K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.